This is a case report of a 52-year-old man who was referred to our institution for radiofrequency (RF) catheter ablation of typical atrial flutter (AFL). The patient was an otherwise healthy man, who presented with palpitations beginning two years pr…
The patient is a 57-year-old white male who has New York Heart Association (NYHA) class III heart failure with left ventricular enlargement and left ventricular ejection fraction of 20%, with left bundle branch block and a QRS width of 154 ms. Despit…
We report the initial results from the clinical trial of the IBI RF ablation system. The system is composed of: 1) a 4-mm tip ablation catheter utilizing a unique thermocouple to enhance tip temperature control; and 2) a computer-controlled radiofreq…
The NYU approach to AF management goes far beyond techniques in the EP lab. Using various resources and processes, AF management is accomplished using the basic laboratory, clinical lab, and extensive patient follow-up. This Bench to Bedside approach…
The physicians at UCSF are considered pioneers in heart disease treatment and research for conditions such as arrhythmia, heart failure, and catheter ablation, which was developed here. UCSF is also home to 11 research institutes, 1,500 laboratories,…
Surgical treatment of atrial fibrillation (AF) remains the most effective therapy for the treatment of this morbid arrhythmia. Success rates vary depending on the approach, but Dr. Cox, creator of the Maze III procedure, has reported efficacies as hi…
A 54-year-old man was referred for radiofrequency (RF) ablation of atrial fibrillation. Paroxysms of atrial fibrillation started four years ago, and were refractory to antiarrhythmic drug treatment with sotalol hydrochloride, flecainide acetate, and…
May 14
NASPE - QT Prolonging Drugs-Basic, Clinical and Regulatory Issues
Location: Washington, DC
Program Chair: Charles Antzelevitch, PhD
CME Category 1 Credit designated by NASPE.
Contact Hours are not available.
May 14 - 17
North American So…
Boston Scientific Corporation announces the market launch of the Blazer RPM advanced navigation and ablation catheter the first bidirectional navigation catheter available in the United States. The Blazer RPM catheter offers physicians the familiar…
CryoCor, Inc., a development stage medical technology company, announced that they continue to accumulate clinical experience with its Cardiac Cryoablation System. This growing experience comes from commercial use of the product in Europe and Asia an…
